OR WAIT null SECS
The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.
Biovian, a contract development and manufacturing organization (CDMO), announced on Feb. 1, 2024 that it was combining with CDMO 3P Biopharmaceuticals to form 3PBIOVIAN under the two companies’ common shareholder, Keensight Capital. The new group, 3PBIOVIAN, will offer end-to-end development and manufacturing services for protein expression systems and viral vectors for both drug substances and drug products from preclinical to commercial phases.
3PBIOVIAN will be a global CDMOoffering microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production. It will also provide fill/finish services for recombinant proteins and viral vectors. The group has manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland.
“We are thrilled about this opportunity and the new chapter for our combined companies. The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market,” said Antti Nieminen, deputy CEO at 3PBIOVIAN, in a press release.
“The combination of technology, capabilities and most importantly, the quality of the human team, positions us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies,” said Dámaso Molero Sánchez, CEO at 3PBIOVIAN, in the release.
“With a combined 40-year track record and a commitment to quality, both companies have always prioritized customer-centric service. The consolidation of these two technically and financially strong players creates a powerful global end-to-end service provider,” said Pierre Remy, managing partner at Keensight Capital, in the release.